Published in Am J Clin Oncol on October 01, 2003
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer (2014) 1.33
Inhaled therapeutics for prevention and treatment of pneumonia. Expert Opin Drug Saf (2009) 0.89
A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am J Clin Oncol (2008) 0.88
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res (2010) 0.87
Acute radiation syndrome (ARS) - treatment of the reduced host defense. Int J Gen Med (2012) 0.87
Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob Agents Chemother (2007) 0.86
Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother (2011) 0.84
The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm. J Inflamm Res (2012) 0.78
Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther (2010) 0.78
Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease. Acta Haematol (2012) 0.76
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. Am J Clin Oncol (2016) 0.75
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood (2008) 3.01
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Parthenogenetic stem cells in nonhuman primates. Science (2002) 2.54
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
In-transit melanoma: an individualized approach. Oncology (Williston Park) (2011) 2.24
Generation of histocompatible tissues using nuclear transplantation. Nat Biotechnol (2002) 1.97
Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer (2003) 1.83
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol (2002) 1.79
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood (2009) 1.74
The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma (2012) 1.72
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J (2010) 1.66
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica (2011) 1.60
Therapy for metastatic melanoma: the past, present, and future. BMC Med (2012) 1.57
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol (2005) 1.48
The diagnosis and management of desmoplastic small round cell tumor: a review. Curr Opin Oncol (2011) 1.48
Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol (2010) 1.46
The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. FASEB J (2012) 1.42
Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant (2008) 1.37
Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol (2006) 1.36
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 1.34
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol (2008) 1.33
Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer (2008) 1.33
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Intraabdominal desmoplastic small round cell tumors: a diagnostic and therapeutic challenge. Cancer (2005) 1.32
18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med (2009) 1.30
Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer (2006) 1.27
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc (2009) 1.25
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol (2011) 1.24
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol (2006) 1.24
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
Vemurafenib for melanoma metastases to the brain. N Engl J Med (2011) 1.21
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Nonhuman primate parthenogenetic stem cells. Proc Natl Acad Sci U S A (2003) 1.19
Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol (2008) 1.17
Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol (2002) 1.16
CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med (2009) 1.15
Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol (2009) 1.14
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 1.14
Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer (2010) 1.14
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc (2008) 1.13
Fitness of cell-mediated immunity independent of repertoire diversity. J Immunol (2007) 1.11
Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol (2005) 1.05
Challenges in the development of effective peptide vaccines for cancer. Mayo Clin Proc (2002) 1.05
Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol (2010) 1.05
Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol (2004) 1.03
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys (2013) 1.02
Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev (2007) 1.00
Clopidogrel-associated autoimmune thrombocytopenic purpura. Catheter Cardiovasc Interv (2004) 1.00
Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group. Cancer (2011) 1.00
Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc (2012) 1.00
Chylothorax in chronic lymphocytic leukemia patient. Am J Hematol (2002) 1.00
Ewing's sarcoma of the humerus mimicking fibrous dysplasia on imaging and biological behavior. Skeletal Radiol (2004) 0.99
Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. J Immunol (2010) 0.98
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol (2007) 0.98
Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. J Vasc Interv Radiol (2012) 0.97
Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol (2010) 0.97
Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology (2013) 0.97
Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res (2010) 0.97
Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc (2004) 0.97
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol (2012) 0.97
Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Cancer (2007) 0.96
Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study. Am J Clin Oncol (2014) 0.95
A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer (2010) 0.95
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood (2011) 0.95
Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 0.95
The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res (2016) 0.94
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res (2005) 0.94
A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer (2007) 0.94
Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma (2014) 0.93
Rare presentations of primary melanoma and special populations: a systematic review. Am J Clin Oncol (2014) 0.92
In utero transplanted human hepatocytes allow postnatal engraftment of human hepatocytes in pigs. Liver Transpl (2013) 0.91
Resistance to acute babesiosis is associated with interleukin-12- and gamma interferon-mediated responses and requires macrophages and natural killer cells. Infect Immun (2003) 0.91
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675. Am J Clin Oncol (2014) 0.91
Treatment of brain metastases from melanoma. Mayo Clin Proc (2003) 0.90
The clinical case for proton beam therapy. Radiat Oncol (2012) 0.90
A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum (2011) 0.88
Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma (2003) 0.88
Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion. Respir Med (2006) 0.88
The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. Int J Radiat Oncol Biol Phys (2013) 0.88
Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift. Clin Cancer Res (2011) 0.88
Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin Cancer Res (2010) 0.87
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. Oncotarget (2013) 0.87
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses (2014) 0.87
Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res (2011) 0.86
Pediatric melanoma: analysis of an international registry. Cancer (2013) 0.86
Emerging therapies for melanoma. Expert Rev Anticancer Ther (2008) 0.86
Fluctuation of systemic immunity in melanoma and implications for timing of therapy. Front Biosci (Elite Ed) (2012) 0.86
Regional lymphatic immunity in melanoma. Melanoma Res (2012) 0.86
Novel therapeutics for the treatment of metastatic melanoma. Future Oncol (2009) 0.86
Expansion of CD16-negative natural killer cells in the peripheral blood of patients with metastatic melanoma. Clin Dev Immunol (2011) 0.86
Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transplantation. Bone Marrow Res (2013) 0.86
Alveolar soft-part sarcoma responsive to intensive chemotherapy. J Pediatr Hematol Oncol (2004) 0.86
New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant (2009) 0.86
The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol (2015) 0.85
Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy. Gynecol Oncol (2013) 0.85